This Article
Right arrow Full Text
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dubik, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Dubik, M.
Related Collections
Right arrow Infectious Diseases
Right arrow International Child Health

AAP Grand Rounds 2:3-4 (1999)
© 1999 American Academy of Pediatrics

INTERNATIONAL HEALTH

Efficacy of Hepatitis A Vaccine

Source: Sagliocca L, Amoroso P, Strofffolini T, et al. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomized trail. Lancet. 1999;353:1136–1139.

The first 20% of the full text of this article appears below.

To evaluate the efficacy of hepatitis A vaccine in preventing secondary infection among susceptible household contacts, a randomized controlled trial was conducted in Naples, Italy, where hepatitis A virus (HAV) infection is endemic. In Italy, routine medical practice does not require post-exposure prophylaxis of HAV with immune globulin (IG) and none of the study participants received IG. Serum samples were taken from household contacts (older than 1 year and younger than 40 years) of sporadic HAV infection index cases at enrollment, at 14 days and at 45 days. Those contacts negative for IgG and IgM anti-HAV at enrollment were considered susceptible. Susceptible . . . [Full Text of this Article]

Mike Dubik, MD, FAAP
Pediatrics, Naval Medical Center, Portsmouth, VA